静脉注射岩舒合并介入治疗原发性肝癌的82例随机对照研究  

Clinical Effects of Yanshu on Primary Hepatic Carcinoma Treated with Interventional Therapy

作　　者：李柱[1] 陈晓秋[1] 李亮[1] 童刚领[1] 彭安[1] 

机构地区：[1]北京大学深圳医院肿瘤内科,深圳518036

出　　处：《肿瘤防治研究》2012年第7期844-846,共3页Cancer Research on Prevention and Treatment

摘　　要：目的探讨岩舒在肝动脉插管化疗栓塞术治疗原发性肝癌的辅助治疗效果。方法选择需实施肝动脉插管治疗的原发性肝癌患者82名,随机分成治疗组42名,对照组40名。治疗组在肝动脉插管化疗栓塞术全程给予岩舒静脉滴注,对照组仅实施肝动脉插管化疗栓塞。比较两组治疗效果、生存率、临床症状及不良反应。结果治疗组和对照组总有效率比较差异无统计学意义。治疗组的24月生存率明显高于对照组(P<0.05)。治疗后治疗组患者肝区疼痛、腹胀、乏力、发热等临床症状较对照组有较大缓解(P<0.05)。治疗组患者骨髓抑制发生率比对照组明显降低(P<0.05),且对肝功能具有明显的保护作用。结论肝动脉插管化疗栓塞术中静脉注射岩舒,可保护肝功能、改善患者的临床症状、降低不良反应。Objective To study the clinical effect of Yanshu on primary hepatic carcinoma treated with interventional therapy.Methods A total of 82 patients with primary hepatic carcinoma were randomly divided into the treatment group（42 cases） and control group（40 cases）.All patients concurrently received TACE,and the treatment group was additionally treated with Yanshu injection.The curative effects,survival period,clinical symptoms and toxic reactions were observed.Results There was no significant difference between two groups in total effective rates（P〈0.05）.However,there were significant differences in 24-months-survival-rates,clinical symptoms and toxic reactions between two groups（P〈0.05）.Conclusion TACE in combination with Yanshu can protect liver function,improve clinical symptoms,reduce toxic effects and prolong survival of patients.

关 键 词：原发性肝癌 TACE 岩舒 

分 类 号：R737.7[医药卫生—肿瘤]